Investors
Information Disclosure
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 AUGUST 20242024.09.02
-
VOLUNTARY ANNOUNCEMENT - PHASE III STUDY RESULTS OF CULMERCICLIB IN COMBINATION WITH FULVESTRANT FOR TREATMENT OF HR+/HER2- ADVANCED BREAST CANCER FOLLOWING ENDOCRINE TREATMENT TO BE PRESENTED AT 2024 CSCO2024.08.29
-
VOLUNTARY ANNOUNCEMENT - POSITIVE RESULTS ON PHASE III STUDY OF ANLOTINIB HYDROCHLORIDE CAPSULE IN COMBINATION WITH PENPULIMAB FOR FIRST-LINE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA2024.08.28
-
VOLUNTARY ANNOUNCEMENT - THREE RESEARCH RESULTS OF "TQC3721 (PDE3/4 INHIBITOR)" AND "TQC2731 (TSLP MONOCLONAL ANTIBODY)" WILL BE PRESENTED AT ERS 20242024.08.26
-
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 20242024.08.13
-
INTERIM DIVIDEND FOR 20242024.08.13
-
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW INDICATION APPLICATION FOR MARKETING OF BENMELSTOBART INJECTION IN COMBINATION WITH ANLOTINIB HYDROCHLORIDE CAPSULE FOR FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARINOMA2024.08.01
-
NOTIFICATION OF BOARD MEETING2024.07.31